29-Mar-2018
Public Citizen
NAFTA was the first “trade” agreement that included new monopoly powers for Big Pharma companies.
12-Feb-2018
East Asia Forum
Japan’s role in RCEP negotiations appears to have been shaped by its participation in the TPP. Japan is now championing for expanded intellectual property right provisions which may block access to affordable medicines
30-Jan-2018
Parti Sosialis Malaysia
It is now time we open up the dialogue on the kind of trade agreements that we want to see in place.
30-Jan-2018
Knowledge & News Network
India and Cambodia clinch a deal to work towards a Bilateral Investment Treaty which provides financial help to Southeast Asian nations.
17-Jan-2018
The Hindu BusinessLine
India may have to lower the import duty on pharmaceuticals for Peru in the discussions on the proposed free trade agreement (FTA) with the South American country.
12-Jan-2018
The Hindu BusinessLine
The present Indian government has relaunched the talks with Israel. Israel wishes to conduct talks on regular basis to conclude the deal at the earliest. Indian patent system and pharmaceutical related issues have been the reasons why the deal couldn’t progress.
10-Jan-2018
Deccan Herald
India’s position in the RCEP is the most protectionist among all the member nations. India has been resisting demands from Korea & Japan on intellectual property clauses, and other nations on opening up markets.
20-Dec-2017
Health Action International
Negotiations are now nearing completion and there are increasing concerns among public health advocates, patient and consumer organisations, and other stakeholders, both in Europe and the Americas.
9-Nov-2017
The Conversation
The latest plan to get the controversial trade deal up and running involves freezing some of its controversial rules, including rules for biologic drugs, an expensive class of medicines often used to treat conditions such as cancer and rheumatoid arthritis.
25-Oct-2017
Don’t trade our lives away
Access to health products is non-negotiable; the Indian Government should reject the bullying tactics of the US based medical device industry.